Newsletters and Deep Dive digital magazine
Roche/Genentech’s Actemra could have a new use soon, after a successful phase 3 trial in the inflamed artery disease, giant cell arteritis.
The FDA is to quickly review Novartis’s PKC412 (midostaurin) in the blood and bone marrow, acute myeloid leukaemia, with a certain mutation after the drug showed a survival benefit in a lat
GlaxoSmithKline has filed its Shingrix shingles vaccine in the US, seeking approval for prevention of the disease in people aged 50 years or over.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio